Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

20 trials with published results (11%)

Research Maturity

108 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.1%

9 terminated out of 178 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

20%

35 trials in Phase 3/4

Results Transparency

19%

20 of 108 completed with results

Key Signals

20 with results92% success

Data Visualizations

Phase Distribution

105Total
Not Applicable (30)
Early P 1 (3)
P 1 (17)
P 2 (20)
P 3 (17)
P 4 (18)

Trial Status

Completed108
Unknown34
Recruiting10
Terminated9
Withdrawn9
Not Yet Recruiting3

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 108 completed trials

Clinical Trials (178)

Showing 20 of 20 trials
NCT03278587Not ApplicableCompleted

Village-Integrated Eye Worker Trial II - Pilot

NCT06943599Not ApplicableRecruitingPrimary

Strategies for Improving Linkage-to-Care After Eye Disease Screening

NCT03630562Not ApplicableCompletedPrimary

Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration

NCT07318428Not ApplicableEnrolling By Invitation

AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma

NCT07461441Phase 3Recruiting

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

NCT03963817Active Not RecruitingPrimary

A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)

NCT07424235Completed

Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natural History Cohort

NCT07338461Not ApplicableNot Yet Recruiting

High Resolution Imaging OCT Study

NCT07235527RecruitingPrimary

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

NCT07249216Not ApplicableRecruitingPrimary

Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting

NCT03845582Phase 2Completed

Phase 2/3 Study of ALK-001 in Geographic Atrophy

NCT00734487CompletedPrimary

AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study

NCT05698316Active Not RecruitingPrimary

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression

NCT03076697Enrolling By Invitation

Smartphone Screening for Eye Diseases

NCT07002372Not ApplicableRecruitingPrimary

Effect of Video Viewing on Intravitreal Injection Experience

NCT06694272RecruitingPrimary

Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration

NCT06787482Phase 1Recruiting

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

NCT06918028Not Yet Recruiting

An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings

NCT05003245Phase 3CompletedPrimary

Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

NCT04590196Early Phase 1CompletedPrimary

Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients

Scroll to load more

Research Network

Activity Timeline